Friday, August 26, 2011
Bionor Pharma ASA, of Oslo, Norway, said it plans to conduct an exploratory study of its HIV vaccine candidate, Vacc-4x, in combination with Revlimid (lenalidomide, Celgene Corp.).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.